-+ 0.00%
-+ 0.00%
-+ 0.00%

Bristol Myers Squibb (BMY) Stock Could Be Undervalued On Cash Flow

Simply Wall St·11/15/2026 00:29:46
Listen to the news

Bristol-Myers Squibb has delivered a strong share price run in recent years, and fresh product and pipeline news keeps the story in focus. The open question is whether the current US$63.43 price is fully backed by the cash flows the business is expected to generate.

  • Over the past 3 years the stock has returned 43.7%, which puts real weight on whether that gain is supported by the company’s underlying cash generation.
  • Recent updates around Camzyos, ZENBEXUS and a unified research and development structure can influence assumptions about future treatment uptake, development costs and the timing of Bristol-Myers Squibb’s cash inflows.
  • Prefer to judge Bristol-Myers Squibb on earnings? See what Bristol-Myers Squibb's 14.0x P/E says about the price.

The stock's next move may depend on whether those projected cash flows line up with what the current market price implies for Bristol-Myers Squibb.

To evaluate Bristol-Myers Squibb's US$63.43 share price in relation to its cash flow profile and recent drug developments, you can start with a focused screen of 32 high quality undervalued stocks

Does Bristol-Myers Squibb Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model here is built around Bristol-Myers Squibb’s ability to turn its pipeline into steady cash generation over time. Latest twelve month free cash flow sits at about $9.3b, and the projections used in the 2 Stage Free Cash Flow to Equity model assume this cash engine does not surge higher but rather trends toward gently declining levels through the 2030s.

Those softer long range cash flow estimates still result in an intrinsic value that the DCF suggests is substantially above the current US$63.43 share price. News around Camzyos’ pediatric trial success and the coming unified R&D structure helps explain why the model still embeds meaningful long term cash flows even as individual products like Eliquis face future step downs. Find out what Bristol-Myers Squibb could be worth using our Discounted Cash Flow (DCF) estimate.

The Bristol-Myers Squibb Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this valuation puzzle for Bristol-Myers Squibb leaves off by spelling out which paths for growth, margins and earnings would need to play out for the shares to look materially higher or lower than today’s price. They are available on Simply Wall St's Community page.

Rather than focus on a single multiple or model line, each Narrative lays out the key moving parts behind its fair value view so you can see how those assumptions stack up against Bristol-Myers Squibb's reported results over time.

Bulls in Bristol-Myers Squibb see a reshaped portfolio driving value, while bears think the current price already reflects the good news.

Bull case: 21% undervalued

According to the bullish analyst Narrative on Simply Wall St, the upside hinges on how effectively Bristol-Myers Squibb leans on its next wave of therapies.

"The central thing that has to go right is that Bristol-Myers Squibb successfully converts its late stage platforms in areas like CELMoDs, CAR-T, ADCs, Factor XI inhibition and neuroscience into commercially meaningful products while managing the revenue step down from Eliquis and other legacy assets…"

Discover why this Narrative puts Bristol-Myers Squibb at 21% undervalued.

Bear case: 123% overvalued

TradingClimbers, an investor in the Simply Wall St Community, argues Bristol-Myers Squibb only becomes interesting again if the entry price improves.

"What holds me back is not quality but price. At current levels the stock trades above fair value and above my entry filters…"

Explore why this Narrative puts Bristol-Myers Squibb at 123% overvalued.

Before acting on Bristol-Myers Squibb's valuation, there is one more angle to check

Price and cash flows tell only part of the story, because the people steering Bristol-Myers Squibb and the way their pay packets are structured can tilt long term outcomes in ways the model alone will not show. See who runs Bristol-Myers Squibb and how they are paid.